SL
VIR icon

Salomon & Ludwin’s Vir Biotechnology VIR Stock Holding History

Salomon & Ludwin’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.32K Sell
870
-446
-34% -$4.24K ﹤0.01% 1665
2026
Q1 		$11.9K Buy
1,316
+446
+51% +$3.55K ﹤0.01% 1428
2025
Q4 		$5.04K Hold
870
– – ﹤0.01% 1776
2025
Q3 		$4.99K Buy
+870
New +$4.45K ﹤0.01% 1719

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Salomon & Ludwin's VIR Position: Q2 2026 in Review

Salomon & Ludwin reduced its Vir Biotechnology (VIR) stake by 34% in Q2 2026, selling an estimated $4.24K and leaving 870 shares worth $8.32K. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

Salomon & Ludwin first reported a position in VIR in Q3 2025 and has held it in 4 quarters since. The position peaked at $11.9K in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Salomon & Ludwin held 870 shares of Vir Biotechnology worth $8.32K as of Q2 2026.
  • Salomon & Ludwin sold 446 Vir Biotechnology shares in Q2 2026, an estimated $4.24K.
  • Vir Biotechnology made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1665 holding.
  • Salomon & Ludwin first reported a position in Vir Biotechnology in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's Vir Biotechnology position peaked at $11.9K in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.